175 related articles for article (PubMed ID: 35352168)
1. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
[TBL] [Abstract][Full Text] [Related]
2. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer.
Yonemitsu K; Pan C; Fujiwara Y; Miyasato Y; Shiota T; Yano H; Hosaka S; Tamada K; Yamamoto Y; Komohara Y
Sci Rep; 2022 Jul; 12(1):12007. PubMed ID: 35835809
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. Oral squamous cell carcinoma cell-derived GM-CSF regulates PD-L1 expression in tumor-associated macrophages through the JAK2/STAT3 signaling pathway.
Wang P; Tao L; Yu Y; Wang Q; Ye P; Sun Y; Zhou J
Am J Cancer Res; 2023; 13(2):589-601. PubMed ID: 36895967
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Rong QX; Wang F; Guo ZX; Hu Y; An SN; Luo M; Zhang H; Wu SC; Huang HQ; Fu LW
Mol Cancer; 2021 May; 20(1):80. PubMed ID: 34051805
[TBL] [Abstract][Full Text] [Related]
6. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
[TBL] [Abstract][Full Text] [Related]
7. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
[TBL] [Abstract][Full Text] [Related]
8. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
9. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
10. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
Matsubara E; Shinchi Y; Komohara Y; Yano H; Pan C; Fujiwara Y; Ikeda K; Suzuki M
Med Mol Morphol; 2023 Dec; 56(4):250-256. PubMed ID: 37402054
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
12. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
16. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
17. TNF-α-dependent lung inflammation upregulates PD-L1 in monocyte-derived macrophages to contribute to lung tumorigenesis.
Wen Y; Wang X; Meng W; Guo W; Duan C; Cao J; Kang L; Guo N; Lin Q; Lv P; Zhang R; Xing L; Zhang X; Shen H
FASEB J; 2022 Nov; 36(11):e22595. PubMed ID: 36205325
[TBL] [Abstract][Full Text] [Related]
18. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
[TBL] [Abstract][Full Text] [Related]
19. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
20. Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.
Saito Y; Fujiwara Y; Shinchi Y; Mito R; Miura Y; Yamaguchi T; Ikeda K; Urakami S; Nakashima Y; Sakagami T; Suzuki M; Tabata Y; Komohara Y
Cancer Sci; 2022 Sep; 113(9):3255-3266. PubMed ID: 35633190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
